FierceBiotech

FDA approves Humacyte’s off-the-shelf artery implant for vascular trauma repair

The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed to replace a patient’s damaged artery following traumatic injuries to the ...
Seeking Alpha

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

- Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein - - In a comparison to prior results in the PROOVIT registry, outcomes for ...
Kaleido Scope

New treatment for severe bleeding after injury does not show benefit in clinical trial, UAB trauma surgeon finds

A new technique used to control severe bleeding in injured patients has been found to increase the risk of death, according to new research from the University of Aberdeen, in Scotland, which was led ...
Rolling Out

When bleeding won’t stop and what to do fast

Uncontrolled bleeding represents one of the most alarming medical situations people encounter. While minor cuts and scrapes typically stop bleeding within minutes, persistent bleeding despite proper ...
Nasdaq

Humacyte, Inc. Announces FDA Approval for SYMVESS as First-in-Class Bioengineered Vascular Conduit for Arterial Injury Repair

Humacyte, Inc. has announced that the FDA has granted full approval for SYMVESS, a novel bioengineered human tissue designed for use as a vascular conduit in patients with extremity arterial injuries ...
Nasdaq

Humacyte Announces Economic Value of Symvess in Budget Impact Model Publication

Humacyte, Inc. announced the publication of a Budget Impact Model for its bioengineered human tissue, Symvess, in the Journal of Medical Economics, indicating its cost-effectiveness for hospitals and ...